SCHEMBL4887873

SCHEMBL4887873

Cc1ccc(CN2C(=O)C(=Cc3ccc(-c4ccc(S(N)(=O)=O)cc4)o3)SC2=S)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
MAPT P10636 4/20 0.55
MCL1 Q07820 4/20 0.55
ALPL P05186 1/20 0.55
ALPI P09923 1/20 0.55
ALPG P10696 1/20 0.55
ALDH1A1 P00352 3/20 0.55
RECQL P46063 2/20 0.55
LMNA P02545 1/20 0.55
ALOX12 P18054 1/20 0.55
POLB P06746 6/20 0.54
NPSR1 Q6W5P4 2/20 0.54
EIF4E P06730 1/20 0.54
EIF4G1 Q04637 1/20 0.54
THRB P10828 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
PKM P14618 1/20 0.53
PTPN7 P35236 1/20 0.53
PTPN12 Q05209 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4887869 1.00 MEN1 (0.55) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL3899131 0.91 MEN1 (0.65) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL3899134 0.91 MEN1 (0.65) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL14025838 0.91 MEN1 (0.65) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL5145417 0.90 MEN1 (0.66) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL5145412 0.90 MEN1 (0.66) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL8593504 0.90 MEN1 (0.54) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL8593500 0.90 MEN1 (0.54) MEN1KMT2AMAPTMCL1ALPL
SCHEMBL19021494 0.86 MEN1 (0.73) MEN1KMT2AMAPTMCL1ALDH1A1
SCHEMBL8593201 0.86 DUSP3 (0.61) MEN1KMT2AMAPTMCL1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed
US-20040002526-A1 Phospholipase D inhibitors and uses thereof CELL THERAPEUTICS, INC. 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002526-A1 Phospholipase D inhibitors and uses thereof PLD2, PLD1, PLA2G2D MEN1 3009/4885KMT2A 3403/4885MAPT 4292/4885
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN MEN1 2216/4885KMT2A 1040/4885MAPT 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.